Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.
Wisconsin Eagle/10119314

MILWAUKEE, April 6, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Acadia (NASDAQ: ACAD).  The investigation results from inaccurate statements Acadia may have made regarding its financial results, business operations and prospects.

Click here to learn more about the investigation: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

The investigation focuses on whether Acadia properly disclosed the facts underlying its supplemental new drug application for NUPLAZID® (pimavanserin), which is used for the treatment of hallucinations and delusions associated with dementia.  On March 8, Acadia announced that the FDA had "identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time" with respect to its NUPLAZID® application. On April 5, Acadia announced that the FDA had rejected the NUPLAZID® application because it lacks substantial evidence of effectiveness to support approval.

More on Wisconsin Eagle
If you wish to obtain additional information or have information about this investigation, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995,

We specialize in securities fraud and shareholder litigation.  For more information, please feel free to call us.  Attorney advertising. Prior results do not guarantee similar outcomes.

Ademi LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001


Related Links

Filed Under: Business

Show All News | Report Violation


Latest on Wisconsin Eagle